Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results

References

• Global strategy for the diagnosis, management and prevention of COPDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD) Report2017 Available from. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed March 9, 2018
   Google Scholar
• HASGuide Du parcours de soins. Jun 2014 [French National Authority for Health (HAS). Health care Management in COPD62014 Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/guide_parcours_de_soins_bpco_finale.pdfAccessed November 2016 French
   Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (Gold 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• SauerRHänselMBuhlRRubinRAFreyMGlaabTImpact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational studyInt J Chron Obstruct Pulmon Dis20161189189827217742
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAnzuetoARCarterKTiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trialLancet Respir Med20186533734429605624
   PubMed Web of Science ®Google Scholar
• HoogendoornMCorro RamosIBaldwinMGonzalez-Rojas GuixNRutten-van MölkenMPMHBroadening the perspective of cost-effectiveness modeling in chronic obstructive pulmonary disease: a new patient-level simulation model suitable to evaluate stratified medicineValue in Health2019
   Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• CooperCBCelliBRJardimJRTreadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trialChest2013144249049723558890
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• Choices in methods for economic evaluation, a methodological guide (report)2012Haute Authorité de Santé, Saint-Denis La Plaine, France Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdfAccessed November 2017
   Google Scholar
• Base de données publique des medicaments2017Ministère des Solidarités et de la Santé [Public drug database. Ministry of Solidarity and Health] Available from: http://base-donnees-publique.medicaments.gouv.fr/index.php#resultAccessed November 2017 French
   Google Scholar
• DetournayBPribilCFournierMScope GroupThe scope study: health-care consumption related to patients with chronic obstructive pulmonary disease in FranceValue Health20047216817415164806
   PubMed Web of Science ®Google Scholar
• Dépenses d’Assurance Maladie Inter Régime (DAMIR) from the French Sickness Fund 2016 [Inter-Plan Health Insurance Expenses (DAMIR) from the French Sickness fund 2016]; [database - not publicly available]. French
   Google Scholar
• LaurendeauCChouaidCRocheNTerriouxPGourmelenJDetournayBPrise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011 [Management and costs of chronic pulmonary obstructive disease in France in 2011]Revue des Maladies Respiratoires2015327682691 French25613440
   PubMed Web of Science ®Google Scholar
• Classification commune des Actes Médicaux [Common Classification of Medical Acts] Available from: https://www.ameli.fr/accueil-de-la-ccam/index.phpAccessed November 2017 French
   Google Scholar
• JebrakGInitiativesBPCOCOPD routine management in France: are guidelines used in clinical practice?Rev Mal Respir2010271111820146947
   PubMed Web of Science ®Google Scholar
• CNAMTS (french national health fund)Etude des algorithmes de definition de pathologies dans le système Nationale d’information inter-regimes de l’assurance maladie (SNIIRAM) Caisse Nationale d’Assurance Maladie des travailleurs Salariés [CNAMTS (French national health fund). Study of algorithms to define pathologies in the SNIIRAM from the French national health fund]2015 Available from: https://www.ameli.fr/fileadmin/user_upload/documents/Rapport_Etude_algorithmes_partie1.pdfAccessed January 2018 French
   Google Scholar
• AverageOECDeffective age of retirement versus the normal retirement age2011–2016 Available from: http://www.oecd.org/els/emp/average-effective-age-of-retirement.htmAccessed November 2017
   Google Scholar
• DebaucheEArnaudFGallotPES comptes de la nation en 2015, Insee Première n° 1597Mai2016 [Account of the nation in 2015 Insee number 1597. May 2016] French
   Google Scholar
• BeckSVidalencJUne photographie du marché du travail en 2015, Insee Première n° 1602 Juin2016 [A picture of the job market in 2015. Insse number 1602]. French
   Google Scholar
• LétroublonCZillonizSLa Durée du travail, principaux indicateurs, Dares résultatsn°080Décembre2016 [Duration of the main indicators. DARES Results number 808. December, 2016] French
   Google Scholar
• Communiqué de presse: Coûts de la main d’oeuvre dans l’UE. EURO-STAT. 1er avril. 2016 [Press release. Cost of labor in the UE. EURO-STAT. April, 2016] French
   Google Scholar
• StarkieHJBriggsAHChambersMGJonesPPredicting EQ-5D values using the SGRQValue Health201114235436021402304
   PubMed Web of Science ®Google Scholar
• O’HaganAStevensonMMadanJMonte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVAHealth Econ200716101009102317173339
   PubMed Web of Science ®Google Scholar
• Selya-HammerCGonzalez-Rojas GuixNBaldwinMDevelopment of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in ItalyTher Adv Respir Dis201610539140127405723
   PubMed Web of Science ®Google Scholar
• van BovenJFKocksJWPostmaMJCost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropiumolodaterol for patients with COPD in the NetherlandsInt J Chron Obstruct Pulmon Dis2016112191220127703341
   PubMed Web of Science ®Google Scholar
• BolandMRvan BovenJFKocksJWMapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D valuesValue Health201518229930725773566
   PubMed Web of Science ®Google Scholar
• KruisALStällbergBJonesRCPrimary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an unlock validation studyPLoS One201493e9014524598945
   PubMed Web of Science ®Google Scholar
• HoogendoornMCorro RamosIBaldwinMCost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results [poster abstract]European Respiratory Journal201852Suppl 62PA3153
   Google Scholar
• LucianiLHoogendoornMCorro RamosIPRS49 – Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results in France [poster abstract]Value in Health201821Suppl 3S412
   Web of Science ®Google Scholar